Review Article

Synthesis of Benzimidazole-Sulfonyl Derivatives and Their Biological Activities

Endale Mulugeta and Yoseph Samuel

Department of Applied Chemistry, School of Applied Natural Science, Adama Science and Technology University, P.O.Box 1888, Adama, Ethiopia

Correspondence should be addressed to Endale Mulugeta; endexindex05@gmail.com

Received 21 January 2022; Accepted 21 March 2022; Published 5 April 2022

Copyright © 2022 Endale Mulugeta and Yoseph Samuel. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Currently, the synthesis of new compounds with potential bioactivities has become a central issue in the drug discovery arena. Among these new compounds, benzimidazole-sulfonyl scaffolds have vital applications in the fields of pharmaceuticals industries. Benzimidazole and sulfonyl compounds have remarkable biological activities, such as antibacterial, antifungal, anti-inflammatory, antiproliferative, carbonic anhydrase inhibitory, and α-amylase inhibitory activities. Furthermore, recent literature mentions the synthesis and bioactivities of some benzimidazole-sulfonyl hybrids. In this review, we focus on reviewing the synthesis of these hybrid scaffolds and their various types of biological activities of the compounds.

1. Introduction

Disease resistance is one of the critical problems facing clinical repetition, and finding new effective compounds against multiresistant pathogens is one of the major goals in current biomedical research [1]. Among the heterocyclic compounds known in the literature for their various bioactivities are those with benzimidazole ring and those with sulfonamide moiety, which possess a wide range of medicinal properties. Usually, organic compounds with heterocyclic rings as the core of their chemical scaffolds have shown pharmaceutical activities. Furthermore, isolated natural products having heterocyclic rings are good candidates. Heterocyclic compounds provide distinct characteristics and promising applications in the pharmaceutical industry to discover, develop, and produce drugs. Nowadays, heterocyclic compounds are playing an important role to design and develop drugs with wide applications in the pharmaceutical area [2]. In this feature, benzimidazole anchored sulfonamide moiety has a substantial role in the bioactive compounds. Benzimidazole derivatives have developed a considerable interest in the medical field due to their therapeutic action as antimicrobial [3–6], antitumor [7–10], antihelminthic [11], antihistaminic [12–14], proton pump inhibitors [12, 15] anti-inflammatory [16–18], anticancer [19], antioxidant [20], and antihypertensive [21] drugs. Benzimidazole anchored with other heterocyclic compounds, such as triazole, thiadiazole, oxadiazole, morpholine, piperazine, or piperidine, has exhibited potential bioactivities [22, 23]. The presence of sulfonamide moiety within the heterocyclic template enriches the lipophilic properties of the developed derivatives [24].

In this review, we focus on presenting various synthesis methods of benzimidazole-sulfonanyl hybrid compounds and their biological activities such as antibacterial [25], antifungal [25], antiviral [25], antiproliferative [26], anti-inflammatory [27], carbonic anhydrase inhibitors [28], and alpha-amylase inhibitory [29]. The synthesis protocol of benzimidazole-sulfonamide compounds and their various bioactivities have not yet been well and adequately reviewed. Different scholars claim that the introduction of the sulfonamide moiety to the benzimidazole scaffold will enhance the antibacterial and antifungal activities of the synthesized compound [25]. The chemical structures of benzimidazole-sulfonanyl derivatives are shown in Figure 1.
Sulfonyl-based drugs are recognized as sulfa drugs having sulfonyl moiety, and usually, they are employed for preventive and chemotherapeutic agents towards various bacterial infections [30]. Chemical structures of sulfa drugs with potential pharmaceutical activities having sulfonyl scaffolds such as sulfapyridine (2), sulfadiazine (3), sulfadimidine (4), sulfathiazole (5), sulfafurazole (6), and sulfaguanidine (7) are shown in Figure 2.

2. Synthesis of Benzimidazole-Sulfonyl Derivatives

So far, various literature mention compounds having benzimidazole-sulfonyl scaffold have been prepared for their biological activities. Until now, researchers have tried and searched countless methodologies of the benzimidazole-sulfonyl drug-based compounds through improving the scaffold template. Sulfadiazine, sulfamoxole, and sulfathiazole antibacterial drugs with a sulfonyl moiety are the best-known candidates. Drugs having a sulfonyl scaffold usually show a broad range spectrum of bioactivities. Most compounds containing a sulfonyl moiety exhibited antibacterial activity [30], antifungal activity [31], antiviral activity [32], antiprotozoa activity [33], and anti-inflammatory activity [34] are well known. Moreover, they are used to prepare drugs for the remedy of Alzheimer’s disease [35], rheumatoid arthritis [36], and obesity disease [37]. Recently, the synthesis of benzimidazole-sulfonyl hybrids scaffold and their biological activities have become more popular. Usually, the synthesis of benzimidazole has been conducted through the condensation reaction of o-phenylenediamine with carboxylic acids in the presence of an acid catalyst. Also, benzimidazole is prepared from condensation of o-phenylenediamine with a specific carbonyl compounds such as aldehyde, ketone, ester, amide, acid anhydride, and acid chlorides [38]. Frequently, to perform the condensation reaction, smooth acid catalysts such as hydrochloric acid, p-toluene sulfonic acid, or boric acid are needed commonly [38]. Benzimidazole-sulfonyl derivatives are prepared using the reaction of benzimidazole scaffold with sulfonamide derivatives at standard reaction conditions. Kumar and coworkers reported the synthesis and antimicrobial activities evaluation of novel benzimidazole-sulfonyl derivatives from moderate to excellent activities [39]. Here, compound 14 is prepared in an excellent yield with potential bioactive properties. In the beginning, the key structure 2-mercaptopbenzothiazole (10) was prepared using o-phenylenediamine (8) and carbon disulfide (9) through double condensation reaction protocol at low pH (Figure 3).

Later, compound 10 reacted with chloromethyl benzimidazole (11) moiety in methanol solvent to afford compound 12. Finally, compound 12 is subjected to p-toluene sulfonyl chloride (13a) in the pyridine solvent to provide the target compound 14 in a good yield. Al-blew and coworkers’ triazole-based benzimidazole-sulfonyl hybrids scaffolds synthesized (17a–f) are shown in Scheme 1. The synthesis reaction protocol contains two consecutive reaction steps. In the first step compound, 16 was synthesized using mercaptobenzothiazole (10) as starting material subjected to propargyl bromide (15) in the presence of K2CO3 in the DMF solvent. Then, an azide-alkyne cycloaddition click reaction type was carried out by mixing thiopropargylated benzimidazole (16) with the appropriate sulfa drug azide moiety 17 (a–f), in the presence of copper sulfate and sodium ascorbate additive to afford triazole-benzimidazole-sulfonyl hybrids (18a–f) in excellent yields [40] (Scheme 2 [41]).

New Schiff bases bearing benzimidazole and p-toluene sulfonyl moiety were synthesized and exhibited higher antimicrobial activities [42]. Commercially available o-phenylenediamine (8) condensed with α-chloroacetic acid (19) to afford compound 11 in a good yield. Subsequently, compound 11 was directly subjected to sulfonyl chloride 13a in the presence of triethylamine in DMF solvent to provide benzimidazole-sulfonyl hybrids (18a–f) in excellent yields [40] (Scheme 2 [41]).

New Schiff bases bearing benzimidazole and p-toluene sulfonyl moiety were synthesized and exhibited higher antimicrobial activities [42]. Commercially available o-phenylenediamine (8) condensed with α-chloroacetic acid (19) to afford compound 11 in a good yield. Subsequently, compound 11 was directly subjected to sulfonyl chloride 13a in the presence of triethylamine in DMF solvent to provide benzimidazole-sulfonyl hybrids (18a–f) in excellent yields [40] (Scheme 2 [41]).

Jian-Song and coworkers synthesized a series of benzimidazole-sulfonyl hybrids scaffold [27]. Here, aniline 25 reacted with benzimidazole 11 in the presence of potassium carbonate in acetone solvent to afford compound 26. Furthermore, compound 20 reacted with α-hydroxy benzaldehyde (21) in the presence of potassium carbonate and potassium iodide in acetonitrile solvent to afford compound 22. Finally, compound 22 reacted with 2-amino-1,2-diphenylethanol (23) in ethanol solvent to provide compound (Scheme 3).

According to the Jian-Song research group, the synthesis of compound 30 was accomplished via two consecutive substitution reaction steps as shown in Scheme 5. With this reaction, compound 30 was synthesized via two consecutive reaction steps. Here, aniline 28 reacted with benzimidazole 11 in the presence of potassium carbonate in
acetone solvent to afford compound 29. Compound 29 is directly subjected to sulfonyl chloride 13a in the presence of triethylamine in DMF solvent to afford the target compound 30 in a good to excellent yield [27].

Taha and coworkers synthesized benzimidazole-sulfonyl hybrid scaffold 35 with a potent α-amylase inhibitor [44]. Here, 2-mercaptobenzimidazole (10) refluxed with acyl bromide 31 in the presence of potassium carbonate in acetone to afford compound 32. Subsequently, sulfonyl chloride 13a was refluxed with hydrazine hydrate (33) in methanol solvent to afford compound 34. Finally, compound 32 reacted with tosylhydrazine (34) in the presence of acetic acid and methanol affording compound 35 (Scheme 6) [44].

Milite and coworkers synthesized benzimidazole-sulfonyl hybrid scaffold 45 as a core template with potent carbonic anhydrase inhibitors [45]. Here, aniline 36 was protected using acetate 37 in diethyl ether. The resulting intermediate compound 38 reacted with sulfonic acid 39 to afford sulfonyl chloride derivatives (40). Furthermore, compound 40 reacted with ethylamine in THF to afford nitrobenzene sulfonamide 41. Compound 41 was reduced through palladium/carbon catalyst in the presence of ammonium formate in methanol to afford the corresponding amino derivatives 42. Condensations of benzenesulfonyl 42 with aldehyde 43 in the presence of NaHSO₃ afford compound 44. Finally, hydrolysis of compound 44 provides the target compound 45 (Scheme 7).

Tahlan and coworkers report the synthesis of a series of benzimidazole-sulfonyl derivatives 53 with potent antibacterial and antifungal activities [46]. This compound was prepared using four consecutive steps. In the first step, ethyl-2-(4-nitrophenoxy) acetate (48) was synthesized using the reaction of phenol (46) and ethyl-2-bromoacetate (47). Compound 48 treated with sodium hydroxide in ethanol was converted into the corresponding acid derivative 49. Compounds 49 and 50 through double condensation in the presence of tetrabutylammonium chloride salt provide benzimidazole derivative 51. Finally, through S_N2 substitution reaction, compound 51 reacted with substituted sulfonyl chloride (52) affording benzimidazole derivatives 53a–j (Scheme 8). Naaz and coworkers synthesized new derivatives of benzimidazole-sulfonyl 57–59 with potential antibacterial activities [41]. Benzimidazole-sulfonyl derivative 57 was synthesized via S_N2 substitution reaction of benzimidazole 54–56 and benzene sulfonyl chloride 13 (a–c) in the presence of DMAP as shown in Scheme 9.

Sui and coworkers synthesized benzimidazole-sulfonyl hybrids with potent antibacterial and antifungal activities [47]. Compound 63 was synthesized from pyrimidine 60, benzimidazole 54, and p-amino benzenesulfonamide (62) according to the routes shown in Scheme 10.

Mehta and coworkers synthesized novel benzimidazole derivatives with potential antibacterial and antifungal activities. Here, the target compound 69 was synthesized through three consecutive reaction steps. Compound 67 was synthesized from o-phenylenediamine 8 and anhydride 64 via cyclization reaction. Furthermore, compound 64 converted into compound 67 which is a benzimidazole moiety bearing acetamide substituent. Compound 67 undergoes a substitution reaction type with hydrazine to form benzimidazole bearing phenyl hydrazine 68. Finally, compound 68 and sulfonyl chloride 13 undergo substitution reaction to provide compound 69 in a good yield [43] (Scheme 11 [48]).

Rajasekha and coworkers synthesized biologically active benzimidazole-sulfonyl derivative 70 with potent anti-inflammatory activity [49]. Target compound 70 was synthesized via two steps reactions, in which condensation reaction of o-phenylenediamine 8 and anhydride 64 via cyclization reaction. Furthermore, compound 68 and sulfonyl chloride 13 undergo substitution reaction to provide compound 69 in a good yield [43] (Scheme 11 [48]).

Sulfaguanidine
Sulfadiazine
Sulfathiazole Sulfafurazole
H₂N H₂N H₂N
NH₂
NH₂
H₂N H₂N
H₂N
S NH
O
O
S NH
O
O
N
N
N
Sulfapyridine Sulfadimidine
2
3 4
5 6 7

Figure 2: Chemical structures of sulfa drugs derivatives.

Figure 3: Chemical structures of antibacterial active benzimidazole-sulfonyl derivatives.
Scheme 1: Synthetic scheme towards compound 14.

Scheme 2: Synthetic routes towards 1, 2, 3-triazole benzimidazole-sulfonyl derivatives.
3. Bioactivities of Benzimidazole-Sulfonyl Scaffolds and Their Derivatives

Benzimidazole is heterocyclic aromatic compound with promising drug candidate and broad spectrum of biological activities. Benzimidazole anchored with sulfonyl moiety scaffold and derivatives have showed potent broad-spectrum activities. Here, antibacterial, antifungal, antiproliferative, antiviral, carbonic anhydrase activity, and alpha-amylase inhibitor activities possess benzimidazole-sulfonyl hybrids scaffold as templates for various structures that are briefly discussed [47].

3.1. Antibacterial Activities of Benzimidazole-Sulfonyl Derivatives. Benzimidazole-sulfonyl derivatives have exhibited potent antibacterial activity against various Gram-negative and Gram-positive bacterial strains. Compound 72 exhibited good antibacterial activities against Gram-positive and Gram-negative bacterial with MIC ranging from 0.1 to 0.50 mg/mL. The presence of the p-nitrophenyl methyl ether group at position 2 of N-toluene-sulfonyl bromobenzimidazole (72) and the antibacterial properties of the target compound exhibited good activity (Figure 3) [51].

3.2. Antifungal Activities of Benzimidazole-Sulfonyl Derivatives. Benzimidazole-sulfonyl hybrids also exhibited good antifungal activities [40]. Al-blewi and coworkers synthesized a series of sulfonyl amino benzimidazole derivatives 73 that exhibited good antifungal activities. The evaluation for their antimicrobial activities is against two fungal strains *Candida albicans* and *Aspergillus brasiliensis*, and it inhibited the fungal strains within MIC values range 32–64 μg/mL (Figure 4) [40].

3.3. Antiviral Activities of Benzimidazole-Sulfonyl Derivatives. Tahlan and coworkers reported the synthesis and antiviral activities of novel benzimidazole 74a and 74b derivatives. Compounds 74a and 74b inhibited the growth of human immune deficiency virus type-1 (HIV-1) [46]. Other research groups, Chen and coworkers synthesized and report benzimidazole-sulfonamide derivatives of 75a–f to evaluate their antiviral activities.

Among these novel compounds, 75a and 75b showed antiviral activities impacts against TMV at 500 μg/mL, with relating inhibitory paces of 61.5 and 57.6%, respectively, which were superior to that of ningnanmycin (55.8%) (Figure 5) [51].

3.4. Antiproliferative Activities of Benzimidazole-Sulfonyl Derivatives. Benzimidazole derivatives incorporated sulfonyl scaffolds exhibit antiproliferative activities against cancer cell. Shaharyar and Mazumder synthesized and report novel benzimidazole-sulfonyl derivatives 76 (a-b) with potent antiproliferative activities. Compounds 76 (a-b) were evaluated for their anti-inflammatory activities using acetic acid-induced writhing in mice where indomethacin was used as the standard drug and showed good antiproliferative activities (Figure 6) [52].
3.5. Anti-Inflammatory Activities of Benzimidazole-Sulfonyl Derivatives. Tahlan and coworkers synthesized and report anti-inflammatory active benzimidazole-sulfonyl derivatives 77 (a–c). Compounds 77 (a–c) showed good anti-inflammatory activities, compared to the standard drug indomethacin (Figure 7) [46].

Irfan and coworkers synthesized and report biologically active sulfonamide-coumarin-benzimidazole hybrids 78 (a–c). Among the synthesized compounds, sulfonyl-benzimidazole-coumarin platform 78a showed highly enhanced anticancer activity against HeLa human cervix disease cell line in correlation with the reference compound adriamycin (ADR) (Figure 8) [53].

3.6. Carbonic Anhydrases Inhibitors of Benzimidazole-Sulfonyl Derivatives. Zubrien and coworkers synthesized and reportsulfonyl anchored with benzene or benzimidazole rings 79 (a–f), and these derivatives act as inhibitors of carbonic anhydrases. Carbonic anhydrases are ubiquitous
Scheme 6: Synthetic routes towards compound 35.

Scheme 7: Synthetic routes towards compound 45.
metalloenzymes, which catalyze the reversible hydration reaction of \( \text{CO}_2 \) into protons and bicarbonate [53, 54]. Among these compounds, 79b showed the best inhibitors activities on CA I, II, VII, and XIII exhibiting affinities (Figure 9) [53, 54].

3.7. \( \alpha \)-Amylase Inhibitory Activities of Benzimidazole-Sulfonyl Derivatives. \( \alpha \)-Amylase is hydrolyzed enzyme which comprises of \( \text{Ca}^{2+} \) ion in its active pocket and catalyzes the conversion of starch into monosaccharides glucose and maltose via hydrolysis using water [55]. Hussain and coworkers

![Scheme 8: Synthetic routes towards compound 53 derivatives.](image1)

![Scheme 9: Synthetic routes towards compounds 57–59.](image2)
Scheme 10: Synthetic routes towards compound 63 derivatives.

Scheme 11: Synthetic routes toward compound 69 derivatives.

Scheme 12: Synthetic routes towards compound 7.

Figure 4: Chemical structures of antifungal active benzimidazole-sulfonyl derivatives.
Figure 5: Chemical structures of antiviral active benzimidazole-sulfonyl derivatives.

Figure 6: Chemical structures of antiproliferative active benzimidazole-sulfonyl derivatives.

Figure 7: Chemical structures of anti-inflammatory active benzimidazole-sulfonyl derivatives.

Figure 8: Chemical structures of anti-inflammatory active benzimidazole-sulfonyl derivatives.

Figure 9: Chemical structures of carbonic anhydrases inhibitors active benzimidazole-sulfonyl derivatives.
4. Conclusions

In conclusion, this review summarizes the synthetic protocol of benzimidazole-sulfonyl hybrids and the potential bioactivity of the candidates such as antibacterial, antifungal, antiviral, antiproliferative, anti-inflammatory activity, carbonic anhydrase, and α-amylase inhibitory activities are discussed briefly. Thus, this review will serve as a good collection of literature in the field of pharmaceutical chemistry. A wide variety of benzimidazole derivatives have already been reported, and some are currently being used as active medicaments for the treatment of disease, for instance, wound healing. Still, various research groups are focusing on the development of newer benzimidazole-sulfonyl hybrids with better efficacy, potency, and lesser side effects. This area has got the tremendous potential to come up with new chemical entities of medicinal importance.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] Z. Breiyyeh, B. Jube, and R. Karaman, "Resistance of gram-negative bacteria to current antibacterial agents and approaches to resolve it," Molecules, vol. 25, no. 6, Article ID 1340, 2020.
[2] S. Thakral and V. Singh, "Recent development on importance of heterocyclic amides as potential bioactive molecules: a review," Current Bioactive Compounds, vol. 15, no. 3, pp. 316–336, 2019.
[3] A. Aragón-Muriel, Y. Liscano, Y. Upegui et al., "In vitro evaluation of the potential pharmacological activity and molecular targets of new benzimidazole-based Schiff base metal complexes," Antibiotics, vol. 10, no. 6, p. 728, 2021.
[4] A. Ç. Karaburun, B. Kaya Çavusoğlu, U. Acar Çevik et al., "Synthesis and antifungal potential of some novel benzimidazole-1,3,4-oxadiazole compounds," Molecules, vol. 24, no. 1, p. 191, 2019.
[5] H.-Z. Zhang, S.-C. He, Y.-J. Peng et al., "Design, synthesis and antimicrobial evaluation of novel benzimidazole-incorporated sulfonamide analogues," European Journal of Medicinal Chemistry, vol. 136, pp. 165–183, 2017.
[6] X. Ai, X. Pu, Y. Yi et al., "Synthesis and pharmacological evaluation of novel pleuromutilin derivatives with substituted benzimidazole moieties," Molecules, vol. 21, no. 11, Article ID 1886, 2016.
[7] M. Khalifa, A. Gobouri, F. Kabli, T. Altalhi, A. Almalki, and M. Mohamed, "Synthesis, antibacterial, and anti HepG2 cell line human hepatocyte carcinoma activity of some new potentially benzimidazole-5-(aryldiazenyl)thiazole derivatives," Molecules, vol. 23, no. 12, Article ID 3285, 2018.
[8] V. Onnis, M. Demurtas, A. Deplano et al., "Design, synthesis and evaluation of antiproliferative activity of new benzimidazolohydrazone derivatives," Molecules, vol. 21, no. 5, p. 579, 2016.
[9] J. E. Cheong, M. Zaffagni, L. Chung et al., "Synthesis and anticancer activity of novel water soluble benzimidazole carbamates," European Journal of Medicinal Chemistry, vol. 144, pp. 372–385, 2018.
[10] A. Bistrovic, L. Krsulovic, A. Harej et al., "Design, synthesis and biological evaluation of novel benzimidazole amidines as potent multi-target inhibitors for the treatment of non-small cell lung cancer," European Journal of Medicinal Chemistry, vol. 143, Article ID 1616, 2018.
[11] A. Márquez-Navarro, B. Noguea-Torres, A. Hernández-Campos et al., "Anthelmintic activity of benzimidazole derivatives against Toxocara canis second-stage larvae and Hymenolepis nana adults," Acta Tropica, vol. 109, no. 3, pp. 232–235, 2009.
[12] Y. Bansal and O. Silakari, "The therapeutic journey of benzimidazoles: a review," Bioorganic & Medicinal Chemistry, vol. 20, no. 21, pp. 6208–6236, 2012.
[13] C. D. Hadole, J. D. Rajput, and R. S. Bendre, "Concise on some biologically important 2-substituted benzimidazole derivatives," Current Research in Chemistry, vol. 7, p. 195, 2018.
[14] M. Marinescu, D. G. Tudorache, G. I. Marton et al., "Density functional theory molecular modeling, chemical synthesis, and antimicrobial behaviour of selected benzimidazole derivatives," Journal of Molecular Structure, vol. 1130, pp. 463–471, 2017.
[15] J. M. Shin and N. Kim, "Pharmacokinetics and pharmacodynamics of the proton pump inhibitors," Journal of Neurogastroenterology and Motility, vol. 19, no. 1, pp. 25–35, 2013.
[16] M. Gaba, P. Gaba, D. Uppal et al., "Benzimidazole derivatives: search for GI-friendly anti-inflammatory analgesic agents," Acta Pharmaceutica Sinica B, vol. 5, no. 4, pp. 337–342, 2015.
[17] M. Gaba, S. Singh, and C. B. Mohan, "An emerging scaffold for analgesic and anti-inflammatory agents," European Journal of Medicinal Chemistry, vol. 76, p. 495, 2014.
[18] Y. Bansal, M. Kaur, and O. Silakari, "Benzimidazole-ibuprofen/mesalamine conjugates: potential candidates for multifactorial diseases," European Journal of Medicinal Chemistry, vol. 89, pp. 671–682, 2015.
[19] M. Yousef, A. Ahmed Malki, H. Badr, Y. Elbayaa, and S. Sultan, "Synthesis and anticancer activity of novel benzimidazole and benzothiazole derivatives against HepG2 liver cancer cells," Medicinal Chemistry, vol. 8, no. 2, pp. 151–162, 2012.
[20] I. A. Dvornikova, E. V. Buravlev, I. V. Fedorova, O. G. Shevchenko, I. Y. Chukicheva, and A. V. Kutchin, "Synthesis and antioxidant properties of selected benzimidazole derivatives with isobornylphenol fragments," Russian Chemical Bulletin, vol. 68, no. 5, pp. 1000–1005, 2019.
[21] W. Zhu, X. Bao, H. Ren et al., "N-Phenyl indole derivatives as AT1 antagonists with anti-hypertension activities: design, synthesis and biological evaluation," European Journal of Medicinal Chemistry, vol. 115, pp. 161–178, 2016.
[22] N. Karray, "Synthesis of Some New Benzimidazole derivatives containing chlorine and investigation of their antioxidant and..."
anti-urease activities,” *Journal of the Turkish Chemical Society, Section A: Chemistry*, vol. 5, pp. 965–974, 2018.

[23] J. Ramprasad, N. Nayar, U. Dalimba et al., “Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole-benzimidazole derivatives,” *European Journal of Medicinal Chemistry*, vol. 95, pp. 49–63, 2015.

[24] T. Nasr, S. Bondock, and S. Eid, “Design, synthesis, antimicrobial evaluation and molecular docking studies of some new thiophene, pyrazole and pyridine derivatives bearing sulfisoxazole moiety,” *European Journal of Medicinal Chemistry*, vol. 84, p. 491, 2014.

[25] T. Nasr et al., “Synthesis and biological investigation of some novel sulfonamide derivatives containing benzimidazole moiety,” *International Journal of Pharmacy*, vol. 6, p. 38, 2016.

[26] A. A. Adeboye, K. Mohammd Khan, U. Salaret al., “Shahnaz Perveen 2-Aryl benzimidazoles: synthesis, in vitro α-amylase inhibitory activity, and molecular docking study,” *European Journal of Medicinal Chemistry*, vol. 150, p. 248, 2018.

[27] M. Ashraf, “4-[(1E)-3-(Substituted-phenyl)-3-oxoprop-1-en-1-yl]benzenesulfonamide: design, computational, synthesis, characterization and antibacterial assessment,” *International Journal of Pharma Sciences and Research*, vol. 9, p. 35, 2018.

[28] M. Kumar, K. Ramasamy, V. Manic, R. Mishra, M. Abdul, and E. De Clercq, “Synthesis, antimicrobial, anti-proliferative, antiviral evaluation and QSAR studies of 4-(1-aryl-2-oxo-1,2-dihydro-indol-3-ylidene amino)-N-substituted benzene sulfonylamides,” *Arabian Journal of Chemistry*, vol. 7, p. 396, 2012.

[29] K. Chibale, H. Haupt, H. Kendrick, V. Yardley, A. Saravanamuthu, and A. Fairlamb, “Antiproteozal and cytotoxicity evaluation of sulfonamide and urea analogues of quinacrine,” *Journal of Bioorganic & Medicinal Chemistry Letters*, vol. 11, Article ID 2655, 2001.

[30] A. Camoutsis, A. Geronikaki, A. Ciric, M. Sokovic, P. Zoumpoulakis, and M. Zervou, “Sulfamidina-1, 2, 4-thiadiazole derivatives as antifungal and antibacterial agents: synthesis, biological evaluation, lipophilicity, and conformational studies,” *Chemical and Pharmaceutical Bulletin*, vol. 58, p. 160, 2010.

[31] L. Potey, R. Marathe, and P. Sable, “In vitro Anti-inflammatory activity of quinoxalin sulfonamides,” *International Journal of Chemical Research*, vol. 10, p. 726, 2017.

[32] W. Roush, S. Gwalney, J. Cheng, K. Scheidt, J. McKerrow, and E. Hansell, “Vinyl sulfonate esters and vinyl sulfonamides: potent, irreversible inhibitors of cysteine proteases,” *Journal of the American Chemical Society*, vol. 120, Article ID 10994, 1998.

[33] B. Hu, J. Ellingboe, S. Han, E. Largis, K. Lim, and M. Malamas, “Novel (4-piperidin-1-yl)-phenyl sulfonamides as potent and selective human β3 agonists,” *Journal of Bioorganic & Medicinal Chemistry*, vol. 8, Article ID 2045, 2001.

[34] S. Pandit et al., “Synthesis and in vitro evaluations of 6-(hetero)-aryl-imidazo[1,2-b]pyridazine-3-sulfonamide s as an inhibitor of TNF-α production,” *Journal of Bioorganic & Medicinal Chemistry Letters*, vol. 28, p. 24, 2018.

[35] S. Aaleqal, “Synthetic approaches to benzimidazoles from o-phenylenediamine: a literature review,” *Journal of Saudi Chemical Society*, vol. 21, p. 229, 2017.

[36] T. Nasr et al., “Synthesis and ant-inflammatory activity of quinoxalin sulfonamides,” *International Journal of Research in Pharmacy and Science*, vol. 6, p. 1, 2020.
[51] M. Chen, S. Su, Q. Zhou et al., “Reactive oxygen species mediated diabetic heart disease–mechanisms and therapies,” *Journal of Saudi Chemical Society*, vol. 25, p. 101, 2021.

[52] M. Shaharyar and A. B. Mazumder, “A biologically active compounds,” *Arabian Journal of Chemistry*, vol. 10, p. 157, 2017.

[53] A. Irfan, L. Rubab, M. Rehman et al., “Coumarin sulfonamide derivatives: an emerging class of therapeutic agents Pharmacological Profile of Coumarin Sulfonamide Scaffolds,” *Heterocyclic Communications*, vol. 26, p. 46, 2020.

[54] A. Uslu, T. Maz, A. Nocentini, E. Banoglu, C. Supuran, and B. Çalışkan, “Benzimidazole derivatives as potent and isoform selective tumour-associated carbonic anhydrase IX/XII inhibitors,” *Bioorganic Chemistry*, vol. 95, p. 103, 2020.

[55] S. Hussain, M. Taha, F. Rahim et al., "Synthesis of benzimidazole derivatives as potent inhibitors for α-amylase and their molecular docking study in management of type-II diabetes," *Journal of Molecular Structure*, vol. 1232, Article ID 130029, 2021.